Article
The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy.
ESMO open - 1 Feb 2021
Trullas A, Delgado J, Koenig J, Fuerstenau U, Dedorath J, Hausmann S, Stock T, Enzmann H, Pignatti F
Abstract excerpt
On 2 June 2020, a marketing authorisation valid through the European Union (EU) was issued for encorafenib in combination with cetuximab in adult patients with metastatic colorectal carcinoma (mCRC) with the BRAFV600E mutation who had received prior systemic therapy. Encorafenib plus cetuximab was evaluated in a randomised phase III trial of encorafenib plus binimetinib plus cetuximab versus encorafenib plus...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.